ATTD 2026 symposium highlights
From adoption to optimisation: Helping more people realise the full potential of automated insulin delivery (AID)
Explore the key insights from Insulet’s Advanced Technologies & Treatments for Diabetes (ATTD) 2026 symposium, where leading experts discussed the importance of closing the gap between diabetes guidelines and real-world practice, optimising patient outcomes, and preparing for the future of diabetes care.
Key themes
Closing the AID adoption gap
Presented by
Dr. Roque Cardona-Hernandez, MD
Paediatric Endocrinologist
Sant Joan de Déu Barcelona Children’s Hospital
Barcelona, Spain
Helping more people benefit from AID by reducing barriers and aligning practice with current guidelines.
Optimising patient outcomes from day 1
Presented by
Dr. Grazia Aleppo, MD, FACE, FACP
Endocrinologist and Professor
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States
Practical strategies that can improve time in range (TIR), simplify therapy, and support long-term success.
"AID should be the first option, not the last."
- Dr. Cardona-Hernandez
Closing the AID adoption gap
"There is technology like the Omnipod® 5 that that has confirmed efficacy and safety, shown impressive improvements of outcomes compared to MDI, and it's simple to use."1,*
- Dr. Roque Cardona-Hernandez, MD
Paediatric Endocrinologist
Sant Joan de Deu Barcelona Children's Hospital
Barcelona, Spain
Discover why AID is now considered the preferred standard of care, why adoption still lags behind the evidence, and how accessible AID technology can help simplify life for more people living with type 1 diabetes.
Optimising patient outcomes from day 1
"Omnipod 5 is the triple threat. It shows excellent time in range, very low timing below range, and excellent haemoglobin A1C."2,†
- Dr. Grazia Aleppo, MD, FACE, FACP
Endocrinologist and Professor
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States
Learn practical optimisation strategies—from initial settings to simplified bolusing—that can help improve TIR while reducing burden and ensuring sustained results for people living with type 1 diabetes.
Symposium summary PDF
Access all symposium highlights in a single resource. Download the symposium summary for a concise overview of the key insights and takeaways.
Stay up to date with the latest education and updates
Receive clinical resources, future event notifications, and expert educational webinars and highlights.
Continue exploring Omnipod 5
2. Brown SA, Forlenza GP, Bode BW, et al. Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes. Diabetes Care. 2021;44(7):1630-1640. doi: 10.2337/dc21-0172